We have the pleasure to invite you to attend the IBCD 2018: Innovation and Biomarkers in Cancer Drug Development Conference, which will take place on 29 – 30 November 2018 in Brussels, Belgium.

Organised by the European Organisation for Research and Treatment of Cancer (EORTC), an academic research organization, the US National Cancer Institute (NCI), a governmental institution, the European Medicines Agency (EMA), a regulatory agency, and the American Association for Cancer Research (AACR), a professional scientific association. With the involvement of FDA and PMDA and Health Technology Assessment specialists, it endeavours to build upon the recommendations and action points decided upon at the IBCD2016-edition.

IBCD 2018 will discuss:

• The constantly evolving scientific, methodological and regulatory environment for drug and biomarker development.
• Topics, such as, Health Technology Assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice.
• The emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs.

The preliminary programme will be soon available.